Avantax Advisory Services Inc. Grows Stock Position in Johnson & Johnson (NYSE:JNJ)

Avantax Advisory Services Inc. raised its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 3.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 133,405 shares of the company’s stock after buying an additional 4,134 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Johnson & Johnson were worth $21,793,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Price T Rowe Associates Inc. MD raised its stake in shares of Johnson & Johnson by 18.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Johnson & Johnson by 2.3% in the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after purchasing an additional 421,779 shares during the last quarter. FMR LLC raised its stake in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Johnson & Johnson by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock worth $1,333,545,000 after purchasing an additional 24,505 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $168.31 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The business’s 50 day moving average price is $175.98 and its 200-day moving average price is $171.06. The firm has a market capitalization of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.12. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business’s revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.13 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. SVB Leerink reduced their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Credit Suisse Group initiated coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Atlantic Securities reduced their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Finally, Morgan Stanley reduced their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $181.75.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction on Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the sale, the executive vice president now owns 41,813 shares in the company, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. Insiders have sold 233,611 shares of company stock valued at $40,960,735 over the last ninety days. Insiders own 0.35% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.